As part of our series focussing on medicines in Australia, we have added a product review of the use of trastuzumab deruxtecan in HER2-low unresectable or metastatic breast cancer.
This publication outlines the use of of trastuzumab deruxtecan in previously treated patients with unresectable or metastatic HER2-low breast cancer as shown in the DESTINY-Breast04 trial and provides commentary from Associate Professor Nick Murray, Director of Medical Oncology at the Royal Adelaide Hospital.
Please login below to download this issue (PDF)